BIO FILES AMICUS BRIEF CHALLENGING FTC’S OVERREACH ON MERGER ENFORCEMENT THAT THREATENS DRUG DEVELOPMENT INNOVATION

The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge the Federal Trade Commission (FTC) lawsuit to block the acquisition of Horizon by Amgen. The amicus brief was filed in the U.S. District Court, Northern District of Illinois, Eastern Division.

 In the amicus brief, BIO explains how the FTC’s lawsuit would chill biopharmaceutical mergers across the industry and discusses the lawsuit in the context of broader antitrust law and the FTC’s shift to a legal theory that breaks sharply from traditional antitrust concepts.